Polatuzumab vedotin

Polatuzumab vedotin-piiq is a CD79b-directed antibody-drug conjugate (ADC) consisting of three components: 1) the humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b; 2) the small molecule anti-mitotic agent MMAE; and 3) a protease-cleavable linker maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to the polatuzumab antibody. It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Polatuzumab vedotin-piiq has an approximate molecular weight of 150 kDa. An average of 3.5 molecules of MMAE are attached to each antibody molecule. This product is for research use only.

Product Details
Species Reactivity	Human
Type	Antibody-drug conjugate
ADC antibody	Polatuzumab (Anti-CD79b)
ADC cytotoxin (drug)	MMAE
Immunogen	Human CD79b
DAR (Drug to Antibody Ratio)	~3.5
Purity	99%
Molecular Weight	150kDa
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	100 mM Pro-Ac, 20 mM Arg, pH 5.0